Simvastatin and non‐segmental vitiligo: A new potential treatment option?

There is a paucity of data about the impact of systemic statins on vitiliginous lesions in non‐segmental vitiligo (NSV) patients. To the best of our knowledge, no other studies have considered the correlation between lipid disturbances in vitiligo and vitiligo disease activity (VIDA) score. We sough...

Full description

Saved in:

Bibliographic Details
Published in:	Dermatologic therapy Vol. 35; no. 12; pp. e15969 - n/a
Main Authors:	Shaker, Engi Seif E., Allam, Sherihan H., Mabrouk, Maaly M., Elgharbawy, Nashwa M., Salaam, Shady Fikry Abdel
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 01-12-2022
Subjects:	Dyslipidemia Dyslipidemias - diagnosis Dyslipidemias - drug therapy Humans Lipoproteins, LDL - therapeutic use Non‐segmental Simvastatin Triglycerides Vitiligo Vitiligo - diagnosis Vitiligo - drug therapy Vitiligo Non-segmental Simvastatin Dyslipidemia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	There is a paucity of data about the impact of systemic statins on vitiliginous lesions in non‐segmental vitiligo (NSV) patients. To the best of our knowledge, no other studies have considered the correlation between lipid disturbances in vitiligo and vitiligo disease activity (VIDA) score. We sought in this study to evaluate the influence of simvastatin on vitiliginous lesions in NSV patients with dyslipidemia and study the correlation between VIDA score and lipid profile. This clinical trial started with 120 patients with NSV, 79 patients had dyslipidemia and received simvastatin 80 mg daily (till normalization of lipid profile or for 4 months, which came first) and only 63 patients continued till the end of the study. Lipid profile, vitiligo area severity index and VIDA were assessed before and 6 months after the end of simvastatin use. Serum total cholesterol (TC), triglycerides, high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), very low‐density lipoprotein, and LDL/HDL ratio showed statistically significant increases in the NSV than in the control group (p ˂ 0.001). There was a statistically significant positive correlation between VIDA and serum levels of TC and LDL and with LDL/HDL ratio. Simvastatin significantly improved the lipid profile and significantly decreased VIDA (p < 0.011). Negative moderate correlation was found between the decrease in VIDA and duration of disease (r = −0.562, p < 0.001). Simvastatin 80 mg daily could be a helpful treatment for NSV patients with dyslipidemia, controlling the vitiligo activity and protecting against the hazardous effects of dyslipidemia. Better results can be obtained in patients with short duration of the disease.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1396-0296 1529-8019
DOI:	10.1111/dth.15969